NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 02/28/23
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology ConferenceGlobeNewsWire • 01/12/23
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual MeetingGlobeNewsWire • 12/13/22
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual MeetingGlobeNewsWire • 12/07/22
How Much Upside is Left in NGM Biopharmaceuticals (NGM)? Wall Street Analysts Think 462%Zacks Investment Research • 11/15/22
These Were the Five Best and Worst Performing Small-cap Stocks in October 202224/7 Wall Street • 11/08/22
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual MeetingGlobeNewsWire • 11/04/22
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/04/22
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific MeetingGlobeNewsWire • 11/03/22
After Plunging 59.4% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)Zacks Investment Research • 11/03/22
NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/27/22
After Plunging 76.6% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)Zacks Investment Research • 10/18/22
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular DegenerationGlobeNewsWire • 10/17/22
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular DegenerationGlobeNewsWire • 10/16/22
NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic CancerGlobeNewsWire • 09/13/22
Earnings Preview: NGM Biopharmaceuticals (NGM) Q2 Earnings Expected to DeclineZacks Investment Research • 07/28/22
NGM Biopharmaceuticals (NGM) Soars 6.8%: Is Further Upside Left in the Stock?Zacks Investment Research • 07/20/22